Longboard Pharmaceuticals Announces the Appointment of Highly Accomplished Healthcare Executive Randall Kaye, M.D., as Chief Medical Officer
21 mars 2022 16h01 HE
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial Results
03 mars 2022 16h05 HE
|
Longboard Pharmaceuticals, Inc.
Initiated the Phase 1b/2a PACIFIC Study, evaluating LP352 in participants with developmental and epileptic encephalopathies (DEEs)LP352 demonstrated statistically significant reduction of epileptiform...
Longboard Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
05 janv. 2022 08h30 HE
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
Longboard Pharmaceuticals Appoints Brandi L. Roberts as Chief Financial Officer
21 janv. 2021 08h30 HE
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological...
Longboard Pharmaceuticals Appoints Phillip Schneider and Paul Sekhri to Board of Directors
20 janv. 2021 16h30 HE
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological...